BeiGene rebrands as BeOne Medicines
A closer look into BeiGene’s renewed focus on oncology and its mission to innovate and improve cancer treatments (Issue #310, 765 words, 3.5 minutes)
In a significant corporate transformation, BeiGene, the global biotechnology company, has unveiled its new identity as BeOne Medicines Ltd. This rebranding, as first reported by Fierce Pharma, is a pivotal moment in the company’s 14-year history and underscores its commitment to oncology. Industry analysts view this move as a calculated step to align the firm’s brand with its expanded global presence and evolving mission in the competitive pharma landscape. The rebrand aligns with a broader trend in the pharmaceutical industry, following similar re-organizations by companies such as Johnson & Johnson, which established Kenvue as its OTC products unit in 2022.
According to BeiGene, the “Be” in BeOne symbolizes the goal of cancer patients to “be free of disease,” while “One” represents the unity of the company’s mission to cure cancer. The updated logo emphasizes oncology.
This rebranding comes during a period of substantial growth for the company. BeOne’s flagship blood cancer therapy, Brukinsa, surpassed US$1.3 billion in sales last year, crossing the blockbuster threshold. Additionally, the company is advancing the commercialization of Tevimbra, a PD-1 inhibitor for solid tumours, while making progress on a robust oncology pipeline. The company plans to bring more than ten new medicines into clinical trials this year. BeOne Medicines also continues to expand its global footprint. In July, the company unveiled a US$800 million clinical R&D and manufacturing facility in New Jersey, complementing its headquarters in China and Switzerland.
John V. Oyler, Founder, Chairman, and CEO at BeiGene, shared a post by BeiGene on LinkedIn, adding, “We must all work together, which is why we are committed to uniting the global community against cancer as BeOne.”
THIS WEEK 11/26/24
The U.S. FDA approved BridgeBio Pharma’s acoramidis (Attruby) for treating adults with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).
The U.S. FDA accelerated the approval of Jazz Pharmaceuticals’ zanidatamab-hrii (Ziihera) for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC).
With support from the Government of Ontario through its agency Invest Ontario, Roche Canada announced the addition of up to 250 new informatics jobs in Ontario’s life sciences sector. Most skilled, technical jobs will be in innovative areas such as artificial intelligence, machine learning, computational biology, and data analytics. They will be part of Roche’s Global Informatics function.
Health Canada issued a Notice of Compliance for Johnson & Johnson’s ciltacabtagene autoleucel (Carvykti), which is used to treat adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
NOW LISTEN UP: HERE’S KENNETH CUSTER OF ELI LILLY CANADA
In season 13 of the NPC Podcast, Kenneth Custer, President and General Manager of Eli Lilly Canada, gives insights into his background in neuroscience, innovation in healthcare, and progress in therapeutics for obesity and Alzheimer’s. Hear him in conversation with podcast hosts Mitch Shannon, Jim Shea, and Mark McElwain.
HEALTHBIZ REWIND
This feature of NPC Healthbiz Weekly looks back at some of the most insightful moments from previous NPC Podcast episodes. In Healthbiz Rewind, you’ll read bold life sci predictions made during the renowned “Prognostication Korner” segment of the NPC Podcast.
Brian Bloom
CEO
Bloom Burton & Co
Toronto
Season 12, episode 08
Listen to this episode here
What bold predictions do you have about the life sciences industry over the next 12 to 24 months or even longer?
My most significant prediction is the rise of Canadian-founded and headquartered global champions in our industry. Whether it’s companies like CellCarta in diagnostics, Celera in biotech discovery, Stemcell Technologies in research tools and reagents, or even Apotex as a global pharmaceutical leader, I believe Canada has the potential to produce the equivalent of a Shopify or Research in Motion for health care—something we haven’t seen in a very long time.
INTRODUCING DERMATOLOGY.BUSINESS and the DERMATOLOGY.BUSINESS DEEP DIVE PODCAST
Check out Dermatology.Business, the new newsletter from the same wonderful, supremely talented people who bring you NPC Healthbiz Weekly. Now you can dive deeper into the Dermasphere with our supplemental podcast. Both are published every other Wednesday at precisely 6:00 a.m. EDT. Dermatology.Business has all the breaking news reported directly from the Dermasphere. Find it here and request your free subscription.
NEXT WEEK
It’s easy to get your no-charge subscription to NPC Healthbiz Weekly. We’ll send each issue to your phone or inbox at 6:00 a.m. sharp each Tuesday.
You are receiving this newsletter because you are a client of Chronicle Companies, attended a National Pharmaceutical Congress live event or webinar, or previously requested a subscription to one of our newsletters. If you no longer wish to subscribe to this newsletter, please email the subject line “Unsubscribe NPC Healthbiz” to health@chronicle.org.
NPC Healthbiz Weekly is published by Chronicle Companies, 701 Ellicott Street, Buffalo, N.Y. 14203. Canadian Office: 1460 The Queensway, Suite 212, Etobicoke, Ont. M8Z 1S4
Mitchell Shannon, Publisher; R. Allan Ryan, Editorial Director; John Evans, Joyce Pitters-Hands, Jeremy Visser, Editors; Cristela Tello Ruiz, New Business Development; Amy Elder, Intern; Shannon Abbott, Conferences Organizer.
Content is copyright (c) 2024, Chronicle LifeSci America Corp., except as indicated. Are you interested in contributing to this newsletter or learning about the Chronicle’s services? Please write to us at health@chronicle.org.
Thanks for reading NPC Healthbiz Weekly. Be sure to subscribe to receive new posts directly to your inbox.